Ophthalmology billing requires mastery of eye-specific exam codes versus E/M codes, laterality modifiers, intravitreal injection drug billing, and surgical global periods—a unique combination of rules that demands dedicated specialty expertise. VeriMedix provides ophthalmology-focused RCM that captures every billable service correctly and compliantly.
Ophthalmology operates with a unique parallel coding structure for office visits: ophthalmology-specific eye examination codes (92002–92014) and standard E/M codes (99202–99215) may both be used in ophthalmology practices, but they serve different purposes and cannot be billed together on the same date for the same patient encounter. The eye codes include: 92002 (new patient, intermediate exam), 92004 (new patient, comprehensive), 92012 (established patient, intermediate exam), and 92014 (established patient, comprehensive exam). A comprehensive ophthalmological examination (92004, 92014) requires specific components: history, general medical observation, external ocular structures, ocular motility, pupils, visual fields, ophthalmoscopy, biomicroscopy, and tonometry—it is inherently broader than a focused E/M and includes the initiation of diagnostic and treatment programs. Practices must choose one system consistently per encounter type and ensure documentation meets the criteria for the chosen code. In general, ophthalmology eye codes are preferred for most clinical encounters, but E/M codes are appropriate for medical conditions managed primarily as systemic diseases affecting the eye (e.g., diabetic retinopathy management where significant medical decision-making on systemic conditions is the driver).
Laterality modifiers are essential in ophthalmology billing and are used on virtually every procedural and many diagnostic service. The primary modifiers are -RT (right eye) and -LT (left eye) for bilateral structures; additionally, the E1–E4 eyelid modifiers specify: E1 (upper left eyelid), E2 (lower left eyelid), E3 (upper right eyelid), and E4 (lower right eyelid). These modifiers enable billing the same procedure on both eyes in the same session (e.g., bilateral cataract extraction on two separate encounters) and are required for intravitreal injections, laser treatments, and surgical procedures to correctly identify which eye was treated. Failure to append laterality modifiers to eye procedures causes claim rejection or merging of bilateral services into a single payment, significantly reducing reimbursement.
Intravitreal injection (CPT 67028) is one of the highest-volume procedures in ophthalmology, driven primarily by anti-VEGF therapy for wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion. The injection service (67028) is billed with the appropriate drug J-code: J0178 (aflibercept/Eylea, 1 mg), J2778 (ranibizumab/Lucentis, 0.1 mg), J0172 (brolucizumab/Beovu, 1 mg), and J0179 (faricimab/Vabysmo, 0.1 mg). Bevacizumab (Avastin), compounded for intravitreal use, is billed as J9035 off-label (Medicare reimburses under Part B for wet AMD); NDC reporting and JW/JZ modifiers apply. OCT imaging (92133 for posterior segment, 92134 for optic nerve/RNFL) is frequently performed at injection visits and is separately billable when a distinct clinical decision is made based on the imaging results. Prior authorization requirements for anti-VEGF agents vary widely by commercial payer.
Below are commonly billed codes our certified coders manage for ophthalmology practices. Always confirm payer-specific coverage and current code values.
| Code | Description | Billing note |
|---|---|---|
92004 | Ophthalmological services; new patient, comprehensive examination with initiation of diagnostic and treatment program | New patient comprehensive eye exam; requires all elements: history, external, motility, pupils, VF, ophthalmoscopy, biomicroscopy, tonometry |
92014 | Ophthalmological services; established patient, comprehensive examination with initiation or continuation of diagnostic and treatment program | Established comprehensive eye exam; must document new or modified treatment/diagnostic program; differentiate from 92012 (intermediate) |
67028 | Intravitreal injection of a pharmacologic agent (separate procedure) | Append -RT or -LT; bill drug J-code separately; NDC required; JW/JZ for Medicare; prior auth for most anti-VEGF agents |
J0178 | Injection, aflibercept (Eylea), 1 mg | Anti-VEGF; per 1 mg unit; 2 mg dose = 2 units; HDose Eylea (8 mg) = 8 units; NDC and JW/JZ required for Medicare |
92134 | Scanning computerized ophthalmic diagnostic imaging, posterior segment; with interpretation and report, unilateral or bilateral (OCT retina) | Retinal OCT at intravitreal injection visit; separately billable when independent diagnostic decision is made; requires signed report |
66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis, 1-stage procedure; without endoscopic cyclophotocoagulation | Standard cataract extraction with IOL; global period 90 days; post-op visits included in global; -RT or -LT required |
65855 | Trabeculoplasty by laser surgery, 1 or more sessions (defined treatment series) | Laser for glaucoma (SLT); append -RT or -LT; may be repeated; check payer frequency limits |
92250 | Fundus photography with interpretation and report | Separately billable when performed and interpreted; requires signed report; may bundle with 92004/92014 under some payer policies |
92235 | Fluorescein angiography (includes multiframe imaging) with interpretation and report, unilateral or bilateral | Diagnostic for retinal disease; requires signed interpretation; -26 if interpreting only in facility setting |
Our standard operating procedures for ophthalmology revenue cycle management — the step-by-step workflow we follow on every claim:
These are the issues we see most often in ophthalmology billing — and exactly how we resolve them:
Submitting intravitreal injection (67028), cataract surgery (66984), or laser procedures without -RT or -LT causes claim rejection or payment confusion, particularly when bilateral services are billed. Fix: Configure the billing system to reject or flag any eye procedure claim that lacks a laterality modifier; train coders and billers that virtually every ophthalmology procedure requires a laterality modifier.
Billing both an eye exam code (92004/92012) and an E/M code (99213/99215) for the same encounter on the same date by the same provider causes duplication denials. Fix: Establish practice policy on which code system to use and when; use eye codes for pure ophthalmological exams and E/M codes when systemic disease management is the primary driver; never bill both systems for the same encounter.
Anti-VEGF injections may require PA renewal every 3–6 months or per number of injections. Lapses result in denied drug claims worth thousands of dollars per injection. Fix: Build a PA expiration calendar for all anti-VEGF patients; assign a coordinator to initiate renewal 30 days before expiration with updated VA testing and clinical response documentation.
Billing separate E/M or office visit codes for post-operative visits included in the cataract surgical global period (90 days) results in denials. Fix: Flag all post-op patients in the billing system with their surgical date and global period end date; route any claims during the global period through a global-period review queue; use modifier -79 only for truly unrelated conditions.
CPT 92133/92134 requires a separate signed interpretation report in the medical record. Billing without this documentation results in audit risk and recoupment. Fix: Implement a policy that OCT charges cannot be billed until the physician's signed interpretation is in the chart; use an EHR template that generates the OCT interpretation report linked to the charge.
Verimedix works inside the systems ophthalmology practices already use, including:
Eye codes are preferred for most ophthalmological office visits because they are designed to capture the scope of a comprehensive eye exam, which inherently includes elements not found in a standard E/M (e.g., tonometry, ophthalmoscopy, biomicroscopy). Use E/M codes (99202–99215) when the visit is primarily driven by a medical condition management decision (e.g., managing diabetic retinopathy in the context of systemic diabetes, or a consult requested by another physician focused on a systemic condition). Never bill both code systems for the same encounter.
Yes, if the OCT (92133 or 92134) was independently performed and interpreted to guide a clinical decision—for example, confirming disease activity before administering the injection or evaluating treatment response. A signed, separate interpretation report must be in the chart. Some payers may require a distinct clinical indication in the documentation; append modifier -59 if bundling edits apply.
Bill 67028 twice—once with modifier -RT and once with modifier -LT—on two separate claim lines. Bill the drug J-code for each eye with its respective NDC and appropriate JW/JZ modifier. Most payers reimburse bilateral intravitreal injections at 100% for the first eye and 50% for the second (bilateral surgery payment rules). Verify each payer's bilateral payment policy.
CPT 66984 has a 90-day global period. All routine post-operative office visits related to the cataract surgery within 90 days are included in the global payment. Services NOT included and separately billable include: treatment of complications requiring a return to the operating room, unrelated medical conditions, and the second eye if surgery is performed as a staged procedure (use modifier -58). Document each post-op note clearly.
Compounded bevacizumab for intravitreal use is billed as J9035 (bevacizumab injection, 10 mg) per Medicare. It is used off-label but is reimbursed under Part B for AMD. Bill 67028 with -RT or -LT + J9035 for the amount used, with the compounding pharmacy NDC. Apply JW or JZ modifier for Medicare waste. Note: compounded bevacizumab payment is substantially lower than branded anti-VEGF agents; track cost and reimbursement carefully.
CPT 92015 (determination of refractive state) is a non-covered service under Medicare Part B for both ophthalmologists and optometrists. It is often covered under vision benefits with commercial plans. Ophthalmology practices that perform refractions should use an ABN (Advance Beneficiary Notice) for Medicare patients and collect the refraction fee as a self-pay service. For commercial plans, verify vision benefit coverage before billing.
Verimedix handles the entire ophthalmology revenue cycle — coding, submission, denials, and A/R — so your team can focus on patients.